ELECTROPHYSIOLOGY — Sales to Customers
Products & Services · Sales to CustomersJohnson & Johnson ELECTROPHYSIOLOGY — Sales to Customers remained flat by 0.0% to $2.63B in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 12.4%, from $2.34B to $2.63B. Over 2 years (FY 2022 to FY 2024), ELECTROPHYSIOLOGY — Sales to Customers shows an upward trend with a 15.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand and successful commercial execution in the electrophysiology sector, while a decrease may signal competitive pressure or market saturation.
Detailed definition
This metric represents the total revenue generated from the sale of electrophysiology medical devices and related techno...
Peer comparison
Comparable to revenue segments for cardiac rhythm management or specialized cardiovascular device divisions at major medical technology peers.
jnj_segment_electrophysiology_sales_to_customersHistorical Data
| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | $7.87B | $9.38B | $10.53B |
| YoY Change | — | +19.1% | +12.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's electrophysiology — sales to customers?
- Johnson & Johnson (JNJ) reported electrophysiology — sales to customers of $2.63B in Q4 2024.
- How has Johnson & Johnson's electrophysiology — sales to customers changed year-over-year?
- Johnson & Johnson's electrophysiology — sales to customers increased by 12.4% year-over-year, from $2.34B to $2.63B.
- What is the long-term trend for Johnson & Johnson's electrophysiology — sales to customers?
- Over 2 years (2022 to 2024), Johnson & Johnson's electrophysiology — sales to customers has grown at a 15.7% compound annual growth rate (CAGR), from $7.87B to $10.53B.
- What does electrophysiology — sales to customers mean?
- The total revenue earned from selling electrophysiology medical devices to customers.